JPRN-UMIN000001119已完成2 期
Phase II study of the combination of docetaxel, cisplatin plus S-1(DCS) for advanced or recurrent gastric cancer(KDOG 0601) - Phase II study of DCS for advanced gastric cancer
Department of Gastroenterology, Kitasato University School of Medicine0 个研究点目标入组 45 人开始时间: 2008年4月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients contraindicated to docetaxel,cisplatin,S-1 2)Active infection 3)Severe heart disease 4)Uncontrolled medical conditions (paralytic ileus,bowel obstruciton,interstitial pneumonia,pulmonary fibrosis,uncontrollable diabetes mellitus,renal failure,liver cirrhosis) 5)Massive abdominal effusion or massive pleural effusion 6)Extensive bone metastasis 7)Symptomatic brain metastasis 8)Severe diarrhea 9)Severe mental disorder 10)Histroy of other active malignancy 11)Pregnancy, the desire to preserve 12)Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
已完成
不适用
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40
未知
2 期
A phase II study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.advanced gastric cancerJPRN-UMIN000000801Dept. of Internal Medicine(4)30
未知
2 期
A Phase II study of docetaxel (T) and cyclophosphamide(C) as adjuvant chemotherapy for patients with high risk, node negative, early stage breast cancerBreast cancerJPRN-UMIN000000493Japan East Cancer Center Breast Cancer Consortium50
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270